Skip to main content

Casdin Capital — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

95
Companies
$8.1B
Total invested
$93.1M
Avg. check
20
Industries
Biotechnology 21Health Care 13Therapeutics 12Medical 10Life Science 6Genetics 5+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4972 of 95
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonSeries Unknown
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Deepcell
April 2025

Deepcell is a life science company specializing in AI-powered single-cell classification and isolation for basic and translational research.

Artificial Intelligence (AI) · Menlo ParkSeries Unknown
Amplo Biotechnology
January 2025

Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.

Biotechnology · La Jolla$2.9M Grant
Umoja Biopharma
January 2025

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

Biopharma · Seattle$100.0M Series C
Xcell Biosciences
December 2024

Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.

Biotechnology · San Francisco$1.4M Undisclosed
Meiogenix
December 2024

Meiogenix is a biotechnology company that develops breeding technologies.

Biotechnology · ParisSeries A
Genome Medical
September 2024

Genome Medical is a telegenomics technology and services company allowing access to genomic-based medicine.

Genetics · South San Francisco$75.3M Series D
Relay Therapeutics
September 2024

Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.

Biotechnology · Cambridge$200.0M Post Ipo Equity
Molecular Assemblies
August 2024

Molecular Assemblies is developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products.

Biotechnology · San Diego$4.0M Grant
Idrx
August 2024

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.

Biotechnology · Cambridge$120.0M Series B
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Series Unknown
Genomic Life
May 2024

Genomic Life offers genomic products.

Employee Benefits · La Jolla$10.0M Series Unknown
Cerevance
April 2024

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.

Biotechnology · Boston$47.0M Series B
Gritstone bio
April 2024

Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.

Biotechnology · Emeryville$32.5M Post Ipo Equity
Remix Therapeutics
January 2024

Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.

Biotechnology · Cambridge$60.0M Series Unknown
Exscientia
December 2023

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

Artificial Intelligence (AI) · Oxford$2.3M Grant
Function Oncology
April 2023

Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform.

Biotechnology · San Diego$28.0M Series A
Generation Bio
March 2023

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Biotechnology · Cambridge$76.0M Post Ipo Equity
Vector Biomed
December 2022

Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company.

Machinery Manufacturing · Gaithersburg$15.0M Series Unknown
Hexagon Bio
October 2022

Hexagon Bio is a data-driven biotech company developing targeted small molecule therapeutics.

Biotechnology · Menlo Park$77.3M Series B
Codiak Biosciences
September 2022

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Biotechnology · San Francisco$20.0M Post Ipo Equity
Invetx
May 2022

Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.

Biopharma · Boston$60.5M Series B
MOMA Therapeutics
May 2022

MOMA Therapeutics operates as a biotechnology company.

Biotechnology · Cambridge$150.0M Series B

Where Casdin Capital invests

Biotechnology21
Health Care13
Therapeutics12
Medical10
Life Science6
Genetics5

About Casdin Capital's portfolio

How many companies has Casdin Capital invested in?

Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Casdin Capital invest in?

Casdin Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 20 different industry categories.

What is Casdin Capital's largest investment?

Among tracked funding rounds, Relay Therapeutics received $200.0M in a Post Ipo Equity round. Casdin Capital's total known invested capital is $8.1B.

What is the average investment size for Casdin Capital?

Casdin Capital's average investment size is $93.1M across its portfolio of 95 companies.

What are Casdin Capital's most recent investments?

Recent Casdin Capital portfolio additions include Auron Therapeutics, A2 Biotherapeutics, Deepcell, Amplo Biotechnology, Umoja Biopharma. These companies were founded in 2020 or later.

Reach the founders behind these 95 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →